IMMUTEP LIMITED

Analyst Reco. Immutep Limited

Equities

IMM

AU000000IMM6

Delayed Australian S.E. Other stock markets 08:20:01 2024-04-29 pm EDT			5-day change	1st Jan Change
0.445 ^AUD	0.00%		+15.58%	+28.99%

Apr. 24	Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	MT
Apr. 24	Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baird Initiates Immutep With Outperform Rating, $7 Price Target	23-08-03	MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating	23-05-18	MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers	22-06-03	CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	21-11-11	PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	21-11-03	PU
Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target	21-08-03	PU
IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target	21-08-03	MT
Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT	21-07-16	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer